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Abstract: Telomeres are repetitive tandem DNA sequences that cap chromosomal ends protecting
genomic DNA from enzymatic degradation. Telomeres progressively shorten with cellular replication
and are therefore assumed to correlate with biological and chronological age. An expanding body of
evidence suggests (i) a predictable inverse association between telomere length, aging and age-related
diseases and (ii) a positive association between physical activity and telomere length. Both hypotheses
have garnered tremendous research attention and broad consensus; however, the evidence for each
proposition is inconsistent and equivocal at best. Telomere length does not meet the basic criteria
for an aging biomarker and at least 50% of key studies fail to find associations with physical activity.
In this review, we address the evidence in support and refutation of the putative associations between
telomere length, aging and physical activity. We finish with a brief review of plausible mechanisms
and potential future research directions.
Keywords: telomeres; aging; physical activity; biomarker; association
1. Introduction
The global population of persons aged 80 years or older will triple by 2050 [1], leading inexorably
to a public health imperative. Current increases in life expectancy exceed concomitant increases in
disease free years, creating a compression of chronic disease burden in old age [2]. Physiological aging
is characterized by cumulative deleterious changes to biological function [3] and is the strongest
non-modifiable predictor of most chronic diseases. Despite this, significant variability exists in the
health impact of aging [4].
The associations between mortality and traditional biomarkers such as blood pressure,
cholesterol and body mass index (BMI) weaken with age [5]. The search for a definitive aging
biomarker is encumbered by the heterogeneity of cellular aging. Post-mitotic cells are not subjected to
the replicative stresses experienced by mitotic cells; therefore, some tissues exhibit greater biological
aging than others. The highly variable human lifespan highlights that the mere passage of chronological
time is not an effective, isolated measure of aging. Biological aging refers to processes that proceed
independently of chronological aging that reduce organismal viability and increase vulnerability.
Telomeres are regarded by many as the heir apparent of aging biomarkers, recording both chronological
and biological age [6,7].
2. Telomere Biology—A Primer
Telomeres are specialized DNA structures that bookend nuclear DNA protecting it from
degradation [8]. Mitotic division imposes a progressive loss of telomeric base pairs (bps) due to
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the inability of DNA polymerases to fully replicate the lagging C-strand [9,10]. This cumulative loss
simultaneously chronicles replicative history and imposes a finite replicative limit. Critical shortening
of telomeres causes eventual disruption of the protective protein shelterin complex [11]. Cells requiring
high replicative capacity express telomerase, a specialized ribonucleoprotein complex that synthesizes
telomeric repeats [12]. Human telomerase consists minimally of two core components; a reverse
transcriptase catalytic subunit (hTERT) and an antisense RNA template (hTERC) [12,13]. Telomeres are
sensitive to a host of stimuli including oxidative stress [14], chronic inflammation [15], BMI [16],
smoking [17], alcohol intake [18], perceived stress [19] and physical activity (PA) [20]. A growing body
of evidence also indicates that telomeres are responsive to habitual PA [20,21].
Despite the telomere’s popular designation as a mitotic clock, the relationship between
telomere length and aging is inconsistent and does not meet the requisite biomarker criteria [22].
Closer examination of the association with PA also reveals inconsistencies and methodological
confounders. The clinical and public interest in the PA-telomere association is predicated upon
several tacit assumptions: (i) mean telomere length is causally associated with biological aging and
age-related pathologies and (ii) PA can lengthen mean telomere length and that in doing so; (iii) PA
will reduce biological aging and disease burden. This review summarizes the current evidence for
and against telomeres as aging biomarkers of aging and potential mediators of exercise-induced
health gains.
3. Cellular Senescence
Cellular senescence is the progressive and irreversible loss of replicative capacity in somatic
cells [23]. Cellular senescence sits astride several paradoxical and seemingly incongruent binary
functions; namely tissue regeneration [24] and tissue dysfunction [25], embryonic development [26]
and organismal aging [27] and tumor promotion [28] and suppression [29]. Senescence is triggered
when the telomeric terminal restriction fragment (TRF) reaches a mean length of 4–7 kb [30]. At this
critical threshold, the protective shelterin complex is disrupted exposing an uncapped double-stranded
chromosome end. This in turn triggers the ataxia telangiectasia mutated (ATM)-p53-p21 axis and
subsequent DNA damage response (DDR) [31], preventing progression into the S-phase of the cell
cycle [32–34].
Replicative senescence refers to proliferative exhaustive driven by telomere loss whilst
stress-induced senescence can be precipitated by oxidative or genotoxic stress, regardless of telomere
length [35]. Replicative senescence is causally implicated in aging and age-related diseases such
as cardiovascular disease (CVD) [36], diabetes [37,38], osteoarthritis [39], glaucoma [40] and
cataracts [41]. In addition to lost proliferative capacity, cellular senescence causes significant changes
in gene expression, epigenetic factors and cell morphology [42]. Senescent cells also acquire a
characteristic secretome known as the Senescence-Associated Secretory Phenotype (SASP) [43].
This largely pro-inflammatory phenotype can initiate senescence in young cells contributing to tissue
dysfunction [25], progression of atherosclerosis [36], cancer [44] and diabetes [37,38].
Replicative exhaustion within the immune system is called immunosenescence; a cluster of
age-related changes resulting in decreased replicative capacity [45,46], shortened telomeres [47],
increased cytokine production [48,49] and increased susceptibility to infectious diseases [50]. Given the
diverse physiological ramifications, senescence may be the causal nexus linking the indirect,
microscopic causes of aging with the direct, macroscopic effects of aging [27].
4. Telomeres and Aging
A clear inverse association exists between chronological age and telomere length. Support of
the causal association between telomeres and aging comes from accelerated aging conditions such
as Dyskeratosis Congenita, Werner’s Syndrome and Hutchinson-Gilford Syndrome. Such progeroid
syndromes are characterized by a sequela of age-associated pathologies precipitated by accelerated
telomere attrition [51–55].
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The American Federation of Aging Research stipulate that any candidate aging biomarker must
satisfy the following criteria [56,57]:
1. It must predict the rate of aging and therefore be a better predictor of lifespan than
chronological age
2. It must reflect and monitor the physiological processes underlying aging
3. It must be a repeatable, unobtrusive and harmless measure
4. It must be testable in animal models
4.1. Criterion 1—Must Predict the Rate of Aging Better than Chronological Age
Human telomere length varies by 5000 to 15,000 bps at birth [58], a measure that exceeds
total average leukocyte telomere length (LTL) shortening throughout adult life [59]. Genome-wide
association studies have identified a host of potential candidate loci associated with LTL
variation [60–65]. Estimates of telomeric bp loss vary between 30–200 bps per division [66,67].
Although variable in magnitude, age-related decreases in LTL are consistently observed [68].
Three recent studies estimated the annual telomere shortening rate at 17.4 [69], 15.6 [70] and 48–67 bps
per chronological year [71]. Paternal age at conception of the offspring is associated with longer
offspring LTL [72–74], yet infant LTL is positively associated with adult telomere attrition rate [75,76].
However, the annual adult attrition rate contributes less to population LTL variation than LTL variation
at birth [77] and attrition rate during the first two decades of life [78,79]. Unlike chronological age,
telomere shortening is not linear; the majority of shortening occurs during the rapid somatic expansion
from birth to puberty [80,81]. Thereafter, adults with either longer or shorter than average LTL tend to
maintain that classification into old age [82,83]. Telomere shortening can be heterogeneous within a
given cell as longer telomeres shorten faster than shorter ones [84–86].
Paradoxically, telomere lengthening has been observed in several longitudinal
studies [75,76,87–95]. When assessed over a 2–6 year period, most individuals shorten or maintain
telomere length; however, 15–44% demonstrate an increase in mean LTL [87,89,96]. The assessment
time course appears important as less lengthening is observed when assessed over a 10 year period [97].
Post-intervention increases in telomere length may be due to actual telomerase-mediated addition of
telomeric DNA or an apparent lengthening due to redistribution of immune cell subsets [98]; a caveat
seldom declared in telomeric research.
More people are living into old age; however, these people eventually die within a very narrow
time span as the finite biological limit of human lifespan is reached [99]. If telomere length reliably
scaled with lifespan, individuals with shorter telomeres would theoretically die off before reaching
the limits of human lifespan. This would result in an age-associated decrease in telomere length
variance known as survivor bias; a phenomenon that has been demonstrated [100,101] and refuted in
the data [102]. Most individuals are not living long enough to reach the critically shortened telomere
threshold referred to as the telomeric brink. It is believed that further increases in longevity will be
limited by telomere length [103]. Given an average starting LTL of 10–15 kilobase pairs, even a yearly
loss of approximately 50 bps should still sustain lymphocyte function well beyond 100 years of age.
This appears to support the theory that the length of the shortest telomere, as opposed to the average
telomere length, triggers cell cycle arrest, genomic instability and senescence [85]. Overall, LTL appears
to add predictive power to health measures but is less effective than chronological age [104]. This may
be due to high variability in LTL at birth and throughout the lifespan.
4.2. Criterion 2—The Capacity to Reflect Physiological Processes
Telomeres possess clear biological plausibility as a candidate aging biomarker, reflecting oxidative
stress, inflammation, replicative history and cellular senescence. Despite that, associations with
age-sensitive functional measures are inconsistent. Several studies have failed to find associations
between LTL and lung function [105], grip strength [18], blood pressure [106] and several measures of
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cognitive function [18,101]. However, a more recent investigation identified associations with lung
function, grip strength, pulse pressure, reaction time, general mental ability and general health [104].
The Newcastle 85+ study assessed associations between a panel of 74 candidate biomarkers and four
health-status measures in a cohort of 852 individuals aged 85 years. Leukocyte telomere length did not
fulfil the criterion of significant association with at least two of the health-status measures [107].
Boonekamp et al. propose that organisms consist of redundancy elements that gradually fail and
replace each other as they buffer and accumulate damage. Death occurs when the last of the elements
are exhausted. Boonekamp et al. further propose that LTL is better viewed as a biomarker of somatic
redundancy than biological aging [108]. The somatic redundancy model fits with two established
telomere observations: (i) that longer telomeres, possessing more redundancy units, shorten faster than
short telomeres [84] and (ii) telomere shortening only becomes detrimental when a critical threshold is
passed [109]. The current evidence indicates that LTL likely reflects pre-pubertal somatic growth and
post-pubertal cellular senescence and oxidative stress [58].
4.3. Criterion 3—A Harmless Repeatable Measure
Most studies measure mean telomere length in circulating leukocytes as physiological proxy for
the target tissue. Conclusions from these studies are predicated upon a supposed correlation between
LTL and target tissue. One study correlated LTL with vascular tissue telomere length [110] and there is
evidence of intra-individual correlation in telomere length between different tissues [111,112]. A more
recent study found correlations with only two (intercostal skeletal muscle and liver) out of twelve
human tissues assessed [113]. Experimental data suggests that differences in telomere length between
tissues are due to tissue-specific attrition rates [114]; however, these rates appears to regress towards a
mean value from adulthood to old age [79].
Mean LTL represents the average telomere length across a heterogeneous cell population. A recent
study rank-ordered telomeres as longest in B cells, then CD4+ and CD8+CD28+ T cells (similar lengths)
and shortest in senescent CD8+CD28- T cells [115]. Telomerase expression is also heterogeneous within
the immune system; being highest in B cells, followed by CD4+ T cells, CD8+CD28+ T cells and lowest
in CD8+CD28- T cells [115]. Exercise is known to transiently modulate the relative proportions of
leukocyte subsets in an intensity-dependent fashion [116]. Therefore, the cellular composition at any
given time point will determine the mean LTL and telomerase activity [115].
Considerable variance exists within and between telomere measurement techniques. At present,
several different protocols can be used to measure telomere length [117]. These range from the
original gold standard Southern blot analysis of terminal restriction fragment (TRF), quantitative
polymerase chain reaction-based techniques (qPCR), through to single telomere length analysis
(STELA), flow and quantitative fluorescence in situ hybridization (flow FISH and Q-FISH respectively).
Each has its own strengths, limitations and coefficient of variation (CV), making comparisons
between studies potentially inaccurate. Data from qPCR and Southern blot are weakly correlated
(r = 0.52) [118]. Comparison between qPCR and flow FISH obtained a similarly weak correlation
coefficient (r = 0.47) [119]. Next generation sequencing (NGS) technology has given rise to new
methods of telomere length measurement. The two key proposed methods both count short reads
that contain telomeric repeats [120] and are appropriate for assessment of mean telomere length
in genome [121]. However, there is considerable variation between NGS methods and qPCR-based
measurements at present [122]. Differences in DNA extraction protocol also significantly influence
telomere length [123]. Similarly, telomerase can also be assessed using multiple protocols and variants
thereof, either directly measuring telomerase products or signals from telomerase-mediated DNA [124].
The likelihood of measurement error in telomere research is high. The inter-individual variation in
LTL can be 5000 to 15,000 bps [58] whilst the yearly shortening rates can vary between 30–100 bps [125].
The majority of telomere research utilizes qPCR which has a CV of 6.45% compared to TRF which has a
CV of 1.74% [117]. Such variation is likely to render many associations non-significant or questionable
at the very least.
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4.4. Criterion 4—Testable in Animal Models
Animal models have significantly furthered the understanding of telomere homeostasis and
disease; however, some inherent limitations affect direct inter-species comparisons. The life expectancy
of a mouse is more than 40 times shorter than that of a human yet mouse telomeres are 5 to
10 times longer [126]. The telomerase enzyme is functionally active in the majority but not all,
murine tissues [127]; as distinct from humans that lack detectable telomerase levels in many somatic
cells [128]. The telomerase-negative mTR−/− mouse was initially developed to examine the role
of telomerase in normal and neoplastic growth [129]. It has since made valuable contributions to
the understanding of telomere regulation. However, in addition to exhibiting telomere dysfunction
and increased end-to-end fusions [129,130], late generation mTR−/− mice can also exhibit a host of
other pathological phenotypes [130–139]. Knock-in of telomerase eliminates many of the degenerative
phenotypes observed in late generation mTR−/− mice [140]. The comparatively sterile laboratory
conditions mice are subjected to remove several negative telomere instigators such as variable diets,
pollution, ultraviolet light and inflammation [141].
Whilst rodents are the most widely used animal models, zebrafish have also been used
extensively in telomere/telomerase research. Their short life, relatively short generation time and an
unlimited capacity to regenerate their fins in 7–10 days makes them a convenient model [142,143].
Expression levels of zebrafish TERT mRNA closely correlate with telomerase activity and in accordance
with most marine species, they appear to maintain telomerase expression in somatic tissues [144].
A telomerase-mutant zebrafish strain has been widely used to study aging phenotypes; however,
it demonstrates aging phenotypes that are far more pronounced than wild-type animals [145].
Telomere/telomerase has also been investigated in avian species [146], primate species [147],
plants [148,149], nematodes [150,151] and Drosophila [152]. Each animal model has made contributions
to the understanding of telomere homeostasis; however, most have physiological discontinuities that
challenge their representativeness of normal human aging.
5. Telomeres and Age-Related Diseases
Variable associations exist between accelerated telomere shortening and age-related diseases
such as CVD [96,153,154], cancer [155], stroke [156] diabetes [157–159], dementia [160–162],
chronic obstructive pulmonary disease [163] and skin disorders [164]. Shorter LTL was initially
associated with coronary artery disease (CAD) in 2001 [165]; with similar CVD associations to
follow [106,153,166–173]. Short LTL but not attrition rate, was recently associated with carotid
atherosclerosis progression [174]. Moreover, short telomeres were more strongly associated with
early-onset than late-onset atherosclerosis. A host of CVD risk factors have also been observationally
associated with shortened LTL including smoking [17], diabetes [158], hypercholesterolemia [175],
hypertension [176], obesity [177], physical inactivity [20], alcohol consumption [178] and psychological
issues [179]. Several other studies have not found associations with blood lipid status [15],
hypertension [15,153], smoking [101,180] and BMI [101,180]. A more recent study found no
associations between LTL and coronary risk factors including cholesterol, triglyceride, HDL-cholesterol,
LDL-cholesterol, smoking, personal or family history of CVD [181].
Three key studies have since failed to find any association between LTL and early
atherosclerosis [173,182,183]. Additionally, a recent study associated long, as opposed to short LTL
with a nearly three-fold higher risk of developing myocardial infarction [184]. Support for a causal link
continues to come from genetic and observational prospective studies using Mendelian randomization
to reduce the likelihood of reverse causation. A cluster of seven alleles associated with shortened LTL
are themselves associated with a 21% increased CAD risk per standard deviation in LTL [185–187].
Despite an abundance of conflicting evidence, the broader scientific consensus is that shortened LTL
represents an increased risk of CVD and likely reflects accelerated leukocyte turnover due to oxidative
stress and inflammation.
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Accumulating evidence indicates an independent pro-telomeric effect of statin treatment [188].
Aspirin decreases oxidative stress and forestalls endothelial cell senescence [189] yet inhibits telomerase
activation in polymorphonuclear neutrophils from carotid plaques [190]. Angiotensin-converting
enzyme (ACE) inhibitors also demonstrate a pro-telomeric effect via upregulation of TERT mRNA
in endothelial cells [191]. Androgen treatment also significantly increased LTL in a cohort with
telomere-shortening diseases [192].
The relationship between LTL and cancer is complex and at times paradoxical. A detailed
treatment of the role of telomeres in malignant transformation is beyond the scope of this review.
What follows is a brief overview of current evidence. Telomere shortening and uncapping (loss of
shelterin integrity) are believed to play an anticancer role [193]. Long LTL is associated with
increased risk of several cancer types [194–203]. However, in some instances shortened telomeres can
potentiate cancer by fusing with other uncapped telomeres, thereby creating genome destabilizing
fusion-bridge-breakage cycles [193]. Telomerase activity is a critical component in malignant
transformation with 85–90% of all malignant tumors being telomerase positive [128,204]. It is estimated
that ~15% of human cancers maintain telomere length through one or more mechanisms referred to
as Alternative Lengthening of Telomeres (ALT) [205]. A cluster of seven alleles associated with LTL
homeostasis, TERC, TERT, oligonucleotide/oligosaccharide-binding fold containing one gene (OBFC1),
zinc finger protein 208 (ZNF208), regulator of telomere elongation helicase 1 (RTEL1), acylphosphatase
2 (ACYP2) and nuclear assembly factor 1 ribonucleoprotein (NAF1) are simultaneously associated with
CAD [185] and cancer [195,198]. If the alleles result in comparatively long telomeres, the cancer risk is
elevated and the CAD risk is reduced; the reverse is also true. It has been proposed that the cancer
protection conferred by short telomeres represents an evolutionary trade-off resulting in decreased
proliferative and regenerative capacity [206]. Non-linear U-shaped relationships have been observed
between telomere length and several cancer risk profiles [207]. This may in part be explained by
the destabilizing and potentially oncogenic effects of shortened telomeres [208] and the increased
replicative capacity and potential accumulation of abnormalities associated with longer telomere
length [209].
One proposed explanation for the discrepant associations is that telomere uncapping has
an anti-cancer effect in the young but a potentially pro-cancer effect in the elderly [210].
Hypothetically, the more robust telomere dysfunction-based mechanism of the young would prevent
tumorigenesis whilst the shortened, uncapped and depleted telomeres of the elderly may allow bypass
of aberrant cells [210].
6. Telomeres, Longevity and Mortality
The association with overall longevity is similarly inconsistent. Whilst several studies support an
association with longevity [211–214], just as many refute it [101,180,215,216]. However, the observation
that LTL is longer in women may be linked to the greater longevity observed in women [217].
Additionally, in twin studies, the individual with longer LTL exhibits enhanced longevity compared to
the other twin [218].
A range of studies have identified age-adjusted inverse associations between mean LTL and
all-cause mortality [69,88,160,162,211,212,219–227]. However, other studies were unable to replicate
the association in similar cohorts [18,91,96,101,153,180,215,216,228–230]. Analysis of cohorts from
Costa Rica, Taiwan and United States of America found that after adjustment for gender and age,
LTL ranked between 15th and 17th out of 20 established predictors and biomarkers of all-cause
mortality [231]. A cohort of 4576 healthy individuals had LTL measured twice within a 10-year interval
and were then monitored for morbidity and mortality for another 10 years. Change in LTL and risk
of all-cause mortality were not significantly associated [95]. Despite abundant associations between
telomere length and age-associated mortality, the association diminishes with age [108]; failing to
predict mortality in cohorts of the very old [101,180]. Paradoxically, telomere length in early childhood
most accurately predicts life expectancy [108,232].
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7. Physical Activity and Telomere Length
The widely touted relationship between PA and LTL is replete with inconsistencies.
Support for a positive association has come from a range of observational/cross-sectional
studies [20,179,223,233–248]. A summary of human studies that significantly associated PA with
telomere length is contained in Table 1. Telomere length has been assessed in skeletal muscle cells
and white blood cells (WBCs) in response to aerobic training, resistance training and self-reported PA.
The observed associations appear hormetic, with low and excessive levels of activity associated with
shorter telomeres [241,244] and moderate levels more commonly associated with longer LTL [223].
A 2016 study of 6474 males and females positively associated running with LTL yet found
no associations with other PA domains including aerobics, basketball, bicycling, dancing, running,
stair climbing, swimming, walking and weight-lifting [249]. The authors speculate that the sustained
weight-bearing status of running may preferentially activate signaling pathways, citing other studies
that demonstrated associations in ultra-endurance runners [234]. One can only speculate that
insufficient statistical power explains the lack of association found in other studies employing running
as the independent variable [250,251]. Self-reported PA was positively associated with LTL in a cohort
of 5823 men and women from the National Health and Nutrition Examination Survey (NHANES) [70].
Objectively measured maximal cardiorespiratory fitness (VO2max) has also been positively associated
with LTL in a cohort of obese women [252] and older exercise-trained participants [239].
The positive associations have been refuted by several observational and interventional
studies [15,89,97,250–266]. A summary of human studies that found no significant association between
PA and telomere length is contained in Table 2. A rigorous 2015 systematic review and meta-analysis
concluded that insufficient quality evidence exists to conclusively associate PA with LTL [267].
Approximately 54% of studies reviewed found no relationship between PA and LTL; 41% found a
positive association and 5% identified a curvilinear relationship [267]. Most of the positive associations
were weak to moderate with only two studies reporting strong associations [223,234]. The analysis cited
methodological issues such as weak correlations, assessment of varied tissue types, arbitrary cuff-off
points, inadequate blinding of researchers, selective inclusion of other potentially confounding lifestyle
factors and discrepant measurement techniques as possible confounders [267]. Discrepant modes of
PA and the wide-spread use of self-reported PA with its inherent biases may also explain the lack of
association in several of the studies. A similar review conducted in 2013 assessed the effect of exercise
in animals and humans and identified three general association types: positive association, inverted
“U” response and no association [21].
Whilst some studies identify beneficial chronic effects of exercise on telomere length,
acute telomere shortening has also been observed within the same cohort [268]. A study of 2006 Chinese
participants found no significant difference in LTL across quartiles of PA [266]. Crucially, the author
cited possible decreased role of PA in the seventh decade given potential selection bias of recruiting
healthy elderly participants. A common criticism of studies failing to find associations with
PA is the lack of statistical power; however, a range of studies with sample sizes ranging from
1942–5862 participants have failed to find an association between PA and LTL [15,95,253,264–266]. In a
cohort of 4576 Danish men and women, PA was not associated with LTL change over 10 years [95].
A study by Sun et al. (2012) did not demonstrate an association between PA and LTL in a cohort of
5862 middle-aged women [264]; however, the addition of five low-risk factors (smoking status, PA,
adiposity, alcohol use and diet) to the analysis established a significant association.
Int. J. Mol. Sci. 2017, 18, 2573 8 of 32
Table 1. A summary of studies showing positive associations between physical activity and telomere length.
Ref. Subjects (n) Tissue Measurement Key Findings
[19] 63 healthy post-menopausal women; sedentary group,active group Leukocytes T/S qPCR
Sedentary: one unit increase in the Perceived Stress Scale = 15-fold increase in odds of having
short telomeres (p < 0.05).
Active: Perceived stress unrelated to telomere length (p = 0.45).
[20] White twins 2401: 2152 females, 249 males Leukocytes Southern blot TRF Leisure time PA positively associated with LTL (p < 0.001).LTLs of the most active subjects were 200 nucleotides longer than least active (p = 0.006).
[70] 5823 adult participants; males (n = 2766), females (n = 3057) Leukocytes T/S qPCR
Relative PA (p < 0.0002) and absolute PA (p = 0.0052) associated with longer LTL after
adjustment for demographic variables.
Prevalence of short telomeres associated with relative PA (p < 0.0001).
[179]
1552 Caucasian female twins: 749 dizygotic twins,
27 monozygotic twins. Distributed into six socioeconomic
status (SES) groups
Leukocytes Southern blot TRF
PA positively associated with TRFL (p < 0.005).
Overall decreasing trend in TRFL with lower SES (p < 0.024).
Significant difference in TRFL between non-manual and manual workers (p < 0.01).
[223] 44 healthy, post-menopausal women, divided into habitualexercise and sedentary groups Leukocytes T/S qPCR LTL significantly higher in habitual exercise group compared to sedentary group (p < 0.01).
[233] 274 pairs same sex twins (153 dizygotic pairs,121 monozygotic pairs) Leukocytes Southern blot TRF
LTL is positively associated with self-reported physical ability in all pairs combined (p = 0.006).
Positive association between PA and LTL in all pairs (p = 0.034).
[234] 67 male ultra-marathon runners, 63 age and sex-matchedcontrols Leukocytes T/S qPCR LTL 11% longer in ultra-marathon runners compared to controls (p < 0.001).
[235] Nurse’s health study—7813 females Leukocytes T/S qPCR Moderately or highly active women had 0.07 SD increase in LTL compared to least active(p = 0.02). Greater moderate or vigorous activity associated with longer LTL (p = 0.02).
[236] 392 post-menopausal women with Stage I–III breast cancer PBMCs Southern blot TRF No PA significantly associated with shorter LTL (p = 0.03).
[237] 895 participants: 476 females, 419 males Leukocytes T/S qPCR Low frequency PA an independent predictor of short LTL (p < 0.001).
[238]
944 participants with stable CHD, distributed into
three exercise capacity groups: low (n = 299), moderate:
n = 334, high: n = 381
Leukocytes T/S qPCR LTL significantly longer in subjects with high exercise capacity compared to low (p < 0.001).Association remained after adjustment for CVD severity and physical inactivity (p = 0.005)
[239]
57 participants stratified into four groups: young sedentary
(n = 15), young exercising (n = 10), older sedentary (n = 15),
older exercising (n = 17)
Leukocytes Southern blot TRF
LTL of older exercising subjects significantly longer than age-matched sedentary controls
(p < 0.001). LTL of older exercisers not significantly different from young exercisers (p = 0.12).
LTL positively associated with VO2max (p < 0.01).
[240] 1764 adults: 51% males, 49% females, 73% non-Hispanicwhites; distributed into cardiorespiratory fitness tertiles Leukocytes T/S qPCR LTL longer in upper tertile (p = 0.04) and middle tertile (p = 0.02) compared to lowest tertile.
[241] 69 healthy participants: 34 males, 35 females; distributedinto four exercise energy expenditure quartiles PBMCs T/S qPCR
Significantly longer telomeres in second exercise energy expenditure quartile compared to first
(p = 0.001) and fourth (p = 0.04) quartiles.
[242] 20 male participants: 5 young athletes, 5 youngnon-athletes, 5 older athletes, 5 older non-athletes Skeletal muscle T/S qPCR
Longer telomeres in older athletes compared to older non-athletes (p = 0.04). Young athletes not
different to young non-athletes (p = 0.12).
Strong correlation between VO2max and T/S ratio in athletes (p = 0.02).
[243] 239 post-menopausal women Leukocytes T/S qPCR
One SD below mean PA levels, major life stressors were associated with LTL shortening
(p = 0.008). One SD above mean PA level, major life stressors were not associated with LTL
shortening (p = 0.48).
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Table 1. Cont.
Ref. Subjects (n) Tissue Measurement Key Findings
[244] 782 males: three PA groups low (n = 148), moderate(n = 398), high (n = 236) Leukocytes Southern blot TRF
Inverted “U” response. Moderate PA positively associated with longest LTL (p = 0.03).
LTL the same in low and high PA groups. Moderate PA group had lowest proportion of short
LTL (p = 0.02).
[245]
46 participants distributed into three PA groups:
never trained (n = 15), moderately trained (n = 16),
intensively trained (n = 15)
PBMCs Flow-FISH
T cell TL longer in moderately trained and intensively trained compared to never trained
(p < 0.05).
Significantly longer telomeres in CD8+ T cells in IT group (p < 0.05).
[246] 36 healthy participants distributed into three groups:young (n = 12), old mobile (n = 12), old immobile (n = 12) Skeletal muscle T/S qPCR
Mean TL from leg muscle of the old immobile group was significantly shorter than old mobile
group (p < 0.05), young group (p < 0.05), arm muscle (p < 0.05).
[247]
Young sedentary controls (n = 26), young athletes (n = 32),
middle-aged sedentary
(n = 21), middle-aged athletes (n = 25)
Leukocytes FlowFISH andT/S qPCR
Older sedentary controls had shorter mononuclear cell telomeres than all other groups
(p < 0.001). Age-dependent telomere loss attenuated in lymphocytes (p < 0.001) and
granulocytes (p < 0.001) of older athletes.
[248] 667 healthy adolescents: 169 white males, 179 white females,155 black males, 164 black females Leukocytes T/S qPCR Vigorous PA positively associated with telomere length (p = 0.009)
[249] 6474 participants: 49.6% males, 50.4% females Leukocytes T/S qPCR LTL positively associated with running (p = 0.03)
[268] 20 endurance athletes, 42 age- and gender-matched controls Buccal cells T/S qPCR
Baseline TL better preserved in endurance athletes (p = 0.003).
Intermediate TL reduced in endurance athletes compared to baseline (p = 0.002). Final time
point TL reduced in endurance athletes compared to baseline (p = 0.0006).
[269] 477 healthy males and females Leukocytes T/S qPCR Vigorous PA positively associated with LTL (p < 0.01).
[270] 814 participants: 397 males, 417 females Leukocytes T/S qPCR LTL longer in participants: currently exercising compared to inactive (p = 0.013), engaged inintensive activity (p = 0.011), participating in sport for 10 years prior to assessment (p = 0.017).
[271] 1476 older aged white and African American women Leukocyte Southern blot TRF
Highest self-reported PA associated with longer LTL compared to lowest PA (p = 0.02).
Higher levels of moderate-to-vigorous PA (p = 0.04) and faster walking speed (p = 0.03)
associated with longer LTL.
[272] 582 older adults Leukocytes Southern blot TRF
Greater walking distance (p = 0.007) and better chair test performance (p = 0.04) associated with
longer LTL cross-sectionally. Change in chair test performance associated with less LTL
shortening longitudinally (p = 0.04).
CHD: coronary heart disease. CVD: cardiovascular disease. FlowFISH: fluorescence in situ hybridization combined with flow cytometry. TL: telomere length. LTL: leukocyte telomere
length. PA: physical activity. PBMCs: Peripheral blood mononuclear cells. TRF: terminal restriction fragment analysis. TRFL: terminal restriction fragment length. T/S qPCR: the ratio of
telomere PCR value to single-copy gene value derived from quantitative PCR. SD: standard deviation. SES: socio-economic status. VO2max: maximal volume of oxygen uptake.
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Table 2. A summary of studies showing no association between physical activity and telomere length.
Ref. Subjects (n) Tissue Measurement Key Findings
[15] 2509 participants: males (n = 1218), females (n = 1291) Leukocytes Southern blot TRF Self-reported PA not associated with LTL (p = 0.806).
[89] 608 individuals with stable CAD: 244 males, 364 females Leukocytes T/S qPCR PA did not independently modulate LTL (p = 0.59).
[95] 4576 male and female Danish participants Leukocytes T/S qPCR Change in LTL over 10 years not associated with PA (p = 0.85)
[273] 612 advanced prostate cancer cases 1049 age-matched controls Leukocytes T/S qPCR No significant association between PA and LTL in all subjects combined (p = 0.262).LTL positively associated with healthy lifestyle factors (e.g., diet, PA, smoking) (p = 0.004).
[250] 17 marathon runners15 age- and sex-matched sedentary controls
Lymphocytes
and granulocytes T/S qPCR
No significant difference between marathon runner lymphocyte TL (p = 0.6) and
granulocyte (p = 0.9) compared to controls.
[251] 18 experienced runners, 19 sedentary individuals Skeletal muscle Southern blot TRF
No significant difference in minimum TRF between runners and sedentary (p = 0.805).
Minimum TRF within runners inversely related to years of running (p = 0.007) and hours
spent training (p = 0.035).
[252]
439 overweight and obese women
Randomized into: dietary weight loss (n = 118), aerobic exercise
(n = 117), diet and exercise (n = 117), control (n = 87)
Leukocytes T/S qPCR
No significant difference in LTL in exercise group (p = 0.51), diet and exercise group
(p = 0.14).
Baseline LTL positively associated with VO2max (p = 0.03).
[253] 2284 women (Nurses’ Health Study) Leukocyte T/S qPCR No association between LTL and PA (p = 0.69).
[255] 981 individuals: 467 males, 514 females Leukocytes T/S qPCR Work related PA not associated with LTL (p = 0.933)
[256] 521 obese individuals randomized into: 2 Mediterranean dietgroups, 1 low-fat control group Leukocytes T/S qPCR Self-reported PA not associated with telomere length (p = 0.186).
[257] 190 subjects with impaired glucose tolerance, 188 controls Leukocytes T/S qPCR No significant difference in LTL following multi-faceted lifestyle intervention at 4.5 yearsfollow up (p = 0.76).
[258] 14 individuals, 7 powerlifters, 7 healthy controls Skeletal muscle Southern blot TRF TL not significantly associated with 8 ± 3 years of powerlifting experience (p = 0.07).
[259] 599 healthy males:392 former athletes, 207 controls Leukocytes T/S qPCR
No association between self-reported volume of leisure time PA and LTL in later life
(p = 0.845).
[261] 42 participants: 10 young males, 6 young females, 13 old males,13 old females Skeletal muscle Southern blot TRF
Tibialis anterior telomere length not significantly influenced by self-reported PA
(p value not available).
[262] 16 obese middle-aged women randomized into: exercise group,control group Leukocytes T/S qPCR No significant change in LTL after 6 months of aerobic training.
[263] 136 participants: 50 males, 86 females Lymphocytes T/S qPCR Self-reported PA not associated with longer TL (p = 0.4570).
[264] 5862 women Leukocytes T/S qPCR No association between PA and LTL. Presence of five low-risk healthy lifestyle factorsassociated with longer LTL (p = 0.015).
[265] 1942 male and female participants Leukocytes T/S qPCR PA not significantly associated with LTL in males or females (p-value not available)
[266] 2006 Chinese participants: male (n = 976), female (n = 1030) Leukocytes T/S qPCR No significant difference in TL across quartiles of self-reported PA (p = 0.32)
[274] 84 Caucasian individuals distributed into two groups:exercise trained (n = 44), recreationally active controls (n = 40) PBMCs T/S qPCR
No significant difference in PBMC telomere length between exercising group and controls
(p = 0.72).
[275] 203 healthy participants; African (n = 96), Caucasian (n = 107) Leukocytes T/S qPCR Habitual PA not associated with LTL.
CAD: coronary artery disease. LTL: leukocyte telomere length. PA: physical activity. PBMCs: peripheral blood mononuclear cells. TRF: terminal restriction fragment analysis.
T/S qPCR: the ratio of telomere PCR value to single-copy gene value derived from quantitative PCR. VO2max: maximal volume of oxygen uptake.
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8. Proposed Mechanisms
Despite the positive associations between habitual PA and LTL, a clear mechanistic understanding
of telomeric adaptation is lacking. Following is a summary of the more widely held mechanistic
theories and some candidate mechanisms still subject to further investigation. For a detailed review of
other candidate molecules and signaling pathways, readers should seek out the relevant reviews [21].
9. Telomerase and Physical Activity
Longer telomeres are often inferred by increased telomerase activity; however, levels do not
reliably correlate with telomere length [276]. In a study of 124 health individuals, telomerase activity
progressively decreased in concert with telomere length from ages 4 to 39 years. However, 65% of
individuals aged 40 years or older exhibited low yet stable telomerase expression despite continued
telomere shortening [277].
Mouse models have demonstrated exercise-induced telomerase increases [247,278–280];
however, human results are conflicting. In one study, there was no difference in peripheral blood
mononuclear cell (PBMC) telomerase expression between physical fitness categories [241]. Yet in
another study, endurance-trained athletes demonstrated increased leukocyte telomerase compared to
controls [247]. A 3 month multifaceted intervention consisting of diet, exercise and stress management
techniques increased PBMC telomerase expression; however, direct causation cannot be assigned to
one specific modality [281]. Whilst some interventional studies using acute and intensive exercise
interventions failed to increase leukocyte telomerase expression [260], a recent study elicited increased
PBMC telomerase expression after a single bout of treadmill running [282]. Exercise-induced increases
in hTERT mRNA have been observed; however, a correlation with telomerase enzyme activity can
only be inferred [283].
Telomerase preferentially targets short telomeres [284], therefore acute increases in telomerase
may be an attempt to stabilize critically shortened telomeres [285]. This may explain the increased
telomerase activity and shortened telomeres that accompany subclinical coronary atherosclerosis [286].
10. Oxidative Stress
The accumulation of oxidative stress-induced DNA damage is a key factor in cellular dysfunction
and organismal aging [287], neurodegeneration [288,289], atherosclerosis, diabetes [290] and
carcinogenesis [291]. Telomeric DNA is particularly susceptible to oxidative damage due to
the telomeric G triplet [14,292–294]. Chronic oxidative stress decreases telomeric DNA repair
mechanisms [295], resulting in cumulative and irreparable damage [35]. In doing so, telomeres
chronicle chronic exposure to oxidative stress [296].
Paradoxically, mild exposure to oxidative stress serves a telomere protective function by
increasing anti-oxidant defense systems [262,297–301] and enhancing oxidative damage repair
systems [302]. Cellular antioxidant capacity is correlated with cellular proliferative capacity and
telomere attrition rate [303]. Overexpression of superoxide dismutase reduces telomere shortening in
human fibroblasts [304]. Additionally, under conditions of oxidative stress, telomerase translocates
to the mitochondria where it appears to play a protective function [305,306]. The association
between habitual moderate intensity exercise and longer telomeres [223,273] may be mediated by an
exercise-induced increase in antioxidant defenses. However, a study of obese middle-aged women
demonstrated increases in antioxidant enzymes without concomitant changes in LTL [262].
11. Inflammation
The PA-mediated attenuation of chronic inflammation likely underpins the protective effect
of PA on LTL. Chronic inflammation causes hematopoietic stem cell activation and subsequent
WBC turnover resulting in telomere attrition [307]. Shortened LTL have been associated with
elevated concentrations of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor
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(TNF)-α [308]. Chronic inflammation can also elicit replicative senescence, oxidative stress and
modulation of telomerase activity [309–313]. Shorter mean LTL may reflect an increased burden of
senescent cells which are known to create a pro-inflammatory phenotype [314,315]. Despite the
association, chronic inflammation levels but not LTL predicted successful aging in a cohort of
1554 centenarian, supercentenarians and very old individuals [228].
A consistent inverse association is seen between habitual PA and chronic inflammation [316,317].
The inverted “U” response of telomere homeostasis identified in some studies may be partially
explained by the hormetic inflammatory and oxidative stress response to exercise [318,319].
Whether PA decreases inflammation and subsequent telomere attrition or decreases telomere attrition,
therefore forestalling the onset of senescence-mediated inflammation, remains an open question.
12. The Shelterin Complex
Mouse models have demonstrated exercise-induced plasticity of shelterin components including
Trf2 mRNA [279] and skeletal muscle Trf1 mRNA [320]. Human studies, mostly observational,
have identified increased TRF2 mRNA and protein in young and middle-aged athletes compared to
controls [247]. Increased mRNA expression of leukocyte adrenocortical dysplasia homolog (TPP1) and
hTERT mRNA was also observed in athletes compared to controls [254]. Athletes who performed seven
marathons in one week demonstrated upregulated DNA damage repair enzymes Ku70 and Ku80 in
addition to increased TRF1, TRF2 and Pot-1 mRNA expression. This occurred without concomitant
changes in telomere length or telomerase activity [260]. A single 30 min bout of treadmill running
upregulated WBC hTERT and telomeric repeat binding factor 2 (TERF2IP) mRNA expression in healthy
males [283]. Whilst highly plausible mechanisms, these observations do not infer causation.
13. Epigenetics and Telomere Homeostasis
Telomere length is influenced by a host of epigenetic factors including methylation of sub
telomeric DNA [321–323], histone modification [324,325], posttranslational modifications of shelterin
components [326,327] and non-coding RNAs [328]. An in-depth review of all proposed epigenetic
pathways is beyond the scope of this review. What follows is a brief overview of the current evidence.
MicroRNAs (miRNAs) play critical roles in modulating gene expression via translational
repression or total degradation of the target mRNA [329] MiRNAs mediate several exercise
adaptations [330–334] and demonstrate exercise-induced expression profiles in leukocyte
subsets [335–339]. Exercise-induced increases in WBC miR-186 and miR-96 expression were observed
after a 30-min exercise bout [283]. In silico analysis identified TERF2IP as a potential regulatory target
of miR-186 and miR-96. Telomeric repeat factor 1 is translationally repressed by miR-155 resulting in
chromosome alterations and telomere fragility [328]. Animal models indicate that miR-155 expression
decreases in response to exercise [340]. Expression of TERT mRNA is regulated by miR-498 [341];
however, little is known about the exercise responsiveness of miR-498.
A clear understanding of the role of miRNA-mediated telomere homeostasis is still in its infancy.
The direction of the miRNA-telomere interaction is currently unclear; telomere shortening may actually
cause differential miRNA expression [342]. Most of the established miRNA-telomere associations have
been observed in cancer cell lines, wherein dysregulated telomere maintenance mechanisms may have
corrupted the observed associations. To gain a causal understanding of the role of miRNAs in telomere
homeostasis, gain/loss of function experiments must be conducted in cell lines and animal models.
Accumulating evidence indicates that global DNA methylation may regulate telomere length
variability in adults [343,344]. Associations between DNA methylation and telomere length were
initially established in mice [345]; subsequent human studies identified a positive association between
global DNA methylation at proximal sub telomeric regions and telomerase activity [346]. Little is
currently known about exercise-induced methylation changes within telomeres.
Human telomeres have long been considered transcriptionally silent; however, recent evidence
indicates they are transcribed by RNA polymerase II, producing a class of long noncoding RNA
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(lncRNA) containing telomeric repeats called TERRA [347,348]. TERRA molecules are displaced
from telomeres and recruited to chromosomal ends through interaction with the telomeric structure,
including shelterin components TRF1 and TRF2 [349]. TERRA also interacts with telomeres via the
formation of RNA:DNA hybrid structures known as R-loops [350–353], which are involved with gene
expression regulation [354] and transcription termination [355]. In shortened or damaged telomeres,
TERRA is observed in increased levels [356–358]. Upregulation of TERRA is also observed in instances
of DNA damage or loss of TRF2 [358]. With so much still to learn about lncRNAs such as TERRA,
a full understanding of their potential telomere-regulatory role is several years away.
14. Conclusions
The proposed associations with aging and exercise are biologically plausible. Telomere length
holds tantalizing promise as a biomarker; however, a host of evidential inconsistencies and paradoxes
must be addressed. Leukocyte telomere length is highly variable at birth, a metric influenced by
genetic inheritance and paternal age at conception. It reflects lifelong exposure to oxidative and
inflammatory burden yet childhood LTL has more predictive fidelity than LTL in adulthood or old age.
Oscillating throughout the lifespan, even inexplicably lengthening despite advancing age, mean LTL
differs between genders. Attrition rates also differ between genders and appear dependent upon initial
telomere length. Shortening trajectories can be further influenced by variable exposure to a wide range
of environmental stimuli. The association between PA is more questionable with 50% of studies failing
to find a significant association.
Investigations into plausible mechanisms have returned promising yet inconsistent findings.
The prevailing consensus is that exercise-induced reductions in oxidative stress and inflammation
likely mediate the effect. The possibility that LTL is a physiological epiphenomenon cannot be excluded.
Changes in LTL may simply be coincidental processes that reflect, without directly influencing,
the primary mechanism. It is likely that telomere length per se is significant only in so much as it
reflects the resultant phenotype via pathways such as senescence-associated inflammation.
It has been proposed that evolutionary pressures have fine-tuned telomere length to reduce the risk
of short and long telomere pathologies, namely atherosclerosis and cancer [359–361]. The long-term
consequences of manipulating telomere length are not well understood and should therefore be
approached with equal measures of enthusiasm and evidence.
15. Future Directions
Telomere and telomerase research is on the brink of truly significant contributions to human health
and disease management. Exciting associations and plausible putative mechanisms seem to promise
therapeutic targets for the future. The extensive associations strongly imply causal involvement and
warrant closer, more detailed analysis. We propose four general areas of future research direction.
First, evidence of actual telomere lengthening is lacking. Whether an individual can move from
the lowest to the highest quartile of LTL through lifestyle interventions, presumably with an enhanced
phenotype, remains an open and essential question. Given the propensity for LTL to track through the
lifespan [82], the capacity of PA to modulate a seemingly centrally-driven measure must be addressed.
If actual telomere lengthening is identified, it must then be determined whether such lengthening lies
within the considerable natural ebb and flow of telomere length dynamics over time.
The second future direction regards selection of the most relevant telomeric metric.
Evidence suggests that the proportion of short telomeres may be more consequential than mean
LTL given the ability of very long telomeres within a cell to skew the mean [362,363]. Studies reporting
longer LTL in the physically active should also report the relative proportion of the shortest telomeres.
The third future direction regards the use of mediation analysis to quantify positive and negative
telomere instigators. Mediation analysis models a hypothesized causal chain in which a variable of
interest influences an intervening mediator variable which in turn mediates the outcome variable.
This allows the effect of exposure to the mediator on the outcome variable. Mediation analysis
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quantifies the exposure of likely mediating factors such as oxidative stress, inflammation and age.
Analysis of this sort would also reveal whether changes in telomere length can occur independently
of factors like oxidative stress and inflammation. As an example, a recent study found that fasting
insulin partially mediates the association between genetically determined LTL and CHD risk [364].
The final proposed direction is the development of a regularly updated international consensus
document on telomere research methodology. Developed by an international consortium of leading
telomere researchers, this document could outline: (i) preferred measurement techniques; (ii) acceptable
coefficients of variation; (iii) universally accepted definitions and criteria for long and short telomeres
and (iv) rigorous methods of data interpretation. In time, publishing in accordance with such guidelines
would become the standard expectation with reputational costs incurred for discrepant methodologies.
Many exciting discoveries are undoubtedly yet to come from the field; however, many of
these may be lost to unacceptably large measurement variations and inconsistent methodologies.
The irresistible logicality of the reported telomeric associations risks the premature inference of
causation. The final quantum leap to be made will be the translation of benchtop findings into
clinically relevant interventions. Only then will the ends have justified the means.
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